- Home
- RLYB
RLYB
Rallybio Corporation
as 04-18-2025 12:42pm EST
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 25.0M | IPO Year: | 2021 |
| Target Price: | $11.50 | AVG Volume (30 days): | 194.2K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.22 - $2.00 | Next Earning Date: | 05-08-2025 |
| Revenue: | $636,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Rallybio Corporation News
RLYB Breaking Stock News: Dive into RLYB Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Evercore ISI Downgrades Rallybio to In Line From Outperform
Zacks
10 days ago
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
MT Newswires
10 days ago
HC Wainwright Downgrades Rallybio to Neutral From Buy
Clinical Trials Arena
10 days ago
Rallybio drops drug for rare maternal disorder following Phase II fail
MT Newswires
11 days ago
Rallybio Terminates RLYB212 Development for Rare Immune Disorder; Shares Fall
Business Wire
11 days ago
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
BioPharma Dive
11 days ago
Rallybio discontinues lead drug for rare maternal disorder
Business Wire
a month ago
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Compare RLYB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLYB Rallybio Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.